ARC 01
Alternative Names: ARC-01Latest Information Update: 13 Apr 2022
At a glance
- Originator Araris Biotech
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies; Peptides
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Apr 2022 Pharmacodynamics data from preclinical studies in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Cancer was presented at 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 10 Apr 2021 Preclinical trials in Cancer in Switzerland (IV) prior to April 2021